Annotation Detail

Information
Associated Genes
BTK
Associated Variants
BTK MUTATION
BTK MUTATION
Associated Disease
chronic lymphocytic leukemia
Source Database
DisGeNET
Description
These results reported here provide a molecular mechanistic rationale for clinically evaluating BTK inhibition in AML patients and suggests that in some AML patients the blasts count may initially rise in response to ibrutinib therapy, analgous to similar clinical observations in CLL.
Pubmed
25294819
Section of the abstract supporting the evidence
ALL_TEXT_3/3
Number of the section of the abstract supporting the evidence
3
Number of the sentence supporting the evidence
7
Original source reporting the Gene Disease association
BeFree
DisGENET score for the Gene Disease association
0.00380018620912425
Drugs